Description: ORYX Translational Medicine identifies, finances and develops promising cancer immunotherapy projects in indications with high unmet medical need.
cancer (3398) oncology (609) immunotherapy (111) colorectal cancer (100) translational medicine (21) glioblastoma multiforme (17) therapeutic vaccine (7) hpv-associated cancer (5) oncolytic virus (5) german cancer research center (dkfz)
ORYX’ development strategy bridges the gap between academic research and the pharmaceutical industry for new cancer therapies. Today, the company is developing three clinical cancer immunotherapy projects in indications with high unmet medical need. ORYX is the exclusive licensee of premier cancer immunotherapy substances from the German Cancer Research Center (DKFZ) and the University of Heidelberg. The Company has established close collaborations with DKFZ, Heidelberg University Hospital, National Center
Oncolytic Virus
Oncolytic viruses infect and lyse tumor cells and evoke a strong anti-tumor immune response. ORYX develops the oncolytic parvovirus H1 (H-1PV) which is a wild type rat virus with effects in a broad range of human tumors. Clinical development began in 2011 and continues to show promising results in terms of safety, efficacy and immune response.